Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis
Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis
复制标题
DOI：
10.1136/sextrans-2016-052626
复制
发表时间：
2017-03-01
影响因子：
3.6
通讯作者：
Mesher, D.
中科院分区：
文献类型：
--
作者：
Canvin, M.;Sinka, K.;Mesher, D.
背景 几十年来，英国泌尿生殖医学 (GUM) 诊所对尖锐湿疣的诊断一直在增加。 2008 年，引入了使用二价疫苗（仅限 16 型和 18 型）的国家人乳头瘤病毒 (HPV) 疫苗接种计划。生殖器疣的减少是出乎意料的。然而，自引入疫苗以来，GUM 诊所的尖锐湿疣发病率已显着下降。 方法 使用英格兰各地 GUM 诊所的数据，我们按年龄、性别、性取向和估计疫苗覆盖率分析了尖锐湿疣的发病率。 结果 2009 年至 2014 年间，GUM 诊所的尖锐湿疣诊断率在 15-19 岁的年轻女性中下降了 30.6%， 同龄异性恋青年男性中这一比例为25.4%。总体而言，随着疫苗接种覆盖率的提高，疣的减少程度较高，其中在疫苗接种覆盖率最高的 15 岁年轻女性中观察到的疣诊断下降幅度最大（50.9%）。在同龄男男性行为者 (MSM) 中没有观察到这种下降。 结论 这些生态分析的结果与二价 HPV 疫苗提供适度的针对尖锐湿疣的保护一致。
Background For several decades, diagnoses of genital warts at genitourinary medicine (GUM) clinics in England had been increasing. In 2008, a national human papillomavirus (HPV) vaccination programme was introduced using the bivalent vaccine (types 16 and 18 only). A decrease in genital warts was not anticipated. However, rates of genital warts in GUM clinics have declined significantly since the introduction of the vaccine.Methods Using data from GUM clinics across England, we analysed rates of genital warts by age, gender, sexual orientation and estimated vaccine coverage.Results The reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014 was 30.6% among young women aged 15-19 years and 25.4% among same age heterosexual young men. Overall there was an association showing higher warts reduction with increasing vaccination coverage with the largest declines in warts diagnoses observed in young women aged 15 years (50.9%) with the highest vaccination coverage. No such declines were observed in men who have sex with men (MSM) of the same age.Conclusion The results of these ecological analyses are strongly in keeping with the bivalent HPV vaccine providing modest protection against genital warts.